Ganetespib: research and clinical development.

Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). Int J Oncol (2015) 0.90

Dynamic proteomics reveals bimodal protein dynamics of cancer cells in response to HSP90 inhibitor. BMC Syst Biol (2017) 0.75

Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors. Chemistry (2016) 0.75

Antileukemic Scalarane Sesterterpenoids and Meroditerpenoid from Carteriospongia (Phyllospongia) sp., Induce Apoptosis via Dual Inhibitory Effects on Topoisomerase II and Hsp90. Sci Rep (2016) 0.75

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Res (2017) 0.75

Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci (2017) 0.75

Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling. Int J Oncol (2017) 0.75

Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39

HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98

BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55

Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature (2006) 5.42

Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33

Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res (2012) 4.01

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A (2011) 3.97

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol (2010) 3.15

Hsp90: chaperoning signal transduction. J Cell Physiol (2001) 3.13

Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem (1996) 3.00

HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther (2002) 2.53

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42

Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Clin Cancer Res (2001) 2.35

Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med (Berl) (2004) 2.32

Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta (2011) 2.21

Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res (2003) 2.04

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90

Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol (2013) 1.84

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther (2011) 1.74

Quantitation and intracellular localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol (1984) 1.71

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov (2013) 1.63

Structure and functional relationships of Hsp90. Curr Cancer Drug Targets (2003) 1.59

Heat shock protein 90: inhibitors in clinical trials. J Med Chem (2010) 1.57

Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv Protein Chem (2001) 1.49

Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol (2006) 1.40

Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem (2008) 1.36

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One (2011) 1.31

Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc Natl Acad Sci U S A (2009) 1.29

Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res (2012) 1.26

Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res (2003) 1.22

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther (2012) 1.22

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs (2014) 1.21

HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol (2012) 1.17

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol (2010) 1.14

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg (2001) 1.13

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol (2011) 1.12

Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract (2000) 1.11

Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer Detect Prev (1998) 1.06

Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res (2014) 1.06

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther (2014) 1.04

Molecular pathways: targeting hsp90--who benefits and who does not. Clin Cancer Res (2012) 1.04

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs (2012) 1.03

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer (2013) 1.03

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer (2013) 1.01

BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer (2010) 1.00

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Res Treat (2013) 0.99

KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn (2008) 0.98

A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res (2012) 0.93

A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res (2013) 0.89

Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. Clin Cancer Res (2013) 0.89

Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res (2013) 0.88

Protein chaperones: a composition of matter review (2008 - 2013). Expert Opin Ther Pat (2014) 0.86

ATP-driven molecular chaperone machines. Biopolymers (2013) 0.86

How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery? Ann Surg Oncol (2020) 0.75